Edition:
United States

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

7.13USD
12:52pm EST
Change (% chg)

$0.12 (+1.71%)
Prev Close
$7.01
Open
$7.08
Day's High
$7.20
Day's Low
$6.95
Volume
63,203
Avg. Vol
259,922
52-wk High
$25.11
52-wk Low
$5.91

Select another date:

Mon, Jan 8 2018

BRIEF-Newlink Genetics Outlines 2018 Business Priorities

* NEWLINK GENETICS OUTLINES 2018 BUSINESS PRIORITIES TO SUPPORT PHASE 3 PIVOTAL TRIAL OF INDOXIMOD PLUS PD-1 INHIBITORS

BRIEF-Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement

* NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014

BRIEF-NewLink Genetics reports Q3 loss per share $0.69

* NewLink Genetics Corp - ‍Expect to end 2017 with approximately $150 million in cash and equivalents​

BRIEF-Newlink genetics announces FDA orphan-drug designation for Indoximod

* Newlink Genetics announces FDA orphan-drug designation for Indoximod

BRIEF-NewLink Genetics announces proposed public offering of common stock

* NewLink Genetics announces proposed public offering of common stock

BRIEF-NewLink Genetics forecasts co will have about $100 million in cash and cash equivalents on balance sheet

* NewLink Genetics - forecasts that co will have about $100 million in cash and cash equivalents on its balance sheet as of December 31, 2017 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-NewLink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

* NewLink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

BRIEF-NewLink Genetics announces clinical collaboration with AstraZeneca​

* Newlink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

Select another date: